Edition:
United Kingdom

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.55USD
20 Feb 2018
Change (% chg)

$-0.05 (-3.12%)
Prev Close
$1.60
Open
$1.59
Day's High
$1.60
Day's Low
$1.55
Volume
22,405
Avg. Vol
65,899
52-wk High
$10.90
52-wk Low
$1.48

Chart for

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)
No analyst recommendations are available for .

Overall

Beta: 3.74
Market Cap(Mil.): $22.80
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Cyclacel Pharma Projects Cash Resources To Fund Currently Planned Programs Through End Of 2019

* CYCLACEL PHARMACEUTICALS INC - CO PROJECTS CASH RESOURCES TO FUND CURRENTLY PLANNED PROGRAMS THROUGH END OF 2019 Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia​

07 Sep 2017

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

23 Aug 2017

Competitors

Earnings vs. Estimates